Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Receptor Specificity The peptide binds to GHS-R1a with high affinity, which helps explain its targeted action
The CJC-1295 + Ipamorelin blend is often studied for its potential to synergistically enhance growth hormone secretion through distinct pathways GHRH receptor activation (CJC-1295) and ghrelin receptor stimulation (Ipamorelin)
What community members commonly report: Injection-site reactions (redness, swelling) expected with large-volume subcutaneous injections Mild flu-like symptoms in the 24-72 hours following injection, which some interpret as an immune response to senescent cell die-off Fatigue and general malaise lasting 1-3 days post-injection No noticeable positive effects yet What community members probably will NOT notice: Improved energy or vitality Visible changes in skin, hair, or physical appearance Measurable changes in bloodwork Any performance enhancement Realistic expectation: Week 1 is about initiating the senolytic process
Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH), modified at the N-terminus with a trans-3-hexenoyl group to improve stability
Clinical trials show meaningful weight loss and improved glycemic control
Community reports during the first 2-3 days frequently describe lightheadedness or shakiness if injections are timed away from food
